You have free access to this content

Cancer

Cover image for Vol. 119 Issue 23

1 December 2013

Volume 119, Issue 23

Pages 4055–4211, E1–E3

  1. Issue information

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    1. You have free access to this content
      Issue information (pages i–vii)

      Version of Record online: 1 DEC 2015 | DOI: 10.1002/cncr.29788

  2. CancerScope

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  3. Commentaries

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    1. You have free access to this content
      PD-1 targeting in cancer immunotherapy (pages E1–E3)

      Robert Ferris

      Version of Record online: 5 OCT 2012 | DOI: 10.1002/cncr.27832

      • image

      This Web-only perspective commentary discusses a new class of monoclonal antibodies that have garnered tremendous enthusiasm within the field of cancer immunotherapy, which has previously been hampered by complex, cumbersome agents and cells; individualized and laborious preparations; and questionable clinical efficacy.

    2. You have free access to this content
      A note from history: Landmarks in history of cancer, Part 6 (pages 4058–4082)

      Steven I. Hajdu and Manjunath Vadmal

      Version of Record online: 16 SEP 2013 | DOI: 10.1002/cncr.28319

      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image

      Major events and discoveries in cancer research, diagnosis, and treatment that took place between 1940 and 1970 are reviewed.

  4. Editorial

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    1. You have free access to this content
      From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS (pages 4083–4085)

      Jean-Nicolas Vauthey and Scott E. Kopetz

      Version of Record online: 19 SEP 2013 | DOI: 10.1002/cncr.28348

      Recent studies point to the prognostic value of RAS mutations in patients undergoing resection of colorectal liver metastases. RAS mutation status now offers the option to predict outcome at presentation before response to chemotherapy. It is anticipated that molecular indicators of biological resectability will be increasingly recognized as a complement to the already well-established criteria for technical resectability.

  5. Original Articles

    1. Top of page
    2. Issue information
    3. CancerScope
    4. Commentaries
    5. Editorial
    6. Original Articles
    1. Disease Site

      Gastrointestinal Disease
      You have free access to this content
      Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men (pages 4086–4093)

      Zohar Levi, Jeremy D. Kark, Ari Shamiss, Estela Derazne, Dorit Tzur, Lital Keinan-Boker, Irena Liphshitz, Yaron Niv, Moshe Furman and Arnon Afek

      Version of Record online: 15 OCT 2013 | DOI: 10.1002/cncr.28241

      • image
      • image

      Among the findings of the current study were that having a body mass index at or greater than the 85th percentile during adolescence is associated with the future development of adenocarcinoma of the lower esophagus and gastric cardia. In addition, a lower socioeconomic position at age 17 years is associated with a significantly increased risk of noncardia gastric cancer later in life.

    2. You have free access to this content
      Clinicopathologic characteristics of pancreatic neuroendocrine tumors and relation of somatostatin receptor type 2A to outcomes (pages 4094–4102)

      Kosuke Okuwaki, Mitsuhiro Kida, Tetuo Mikami, Hiroshi Yamauchi, Hiroshi Imaizumi, Shiro Miyazawa, Tomohisa Iwai, Miyoko Takezawa, Makoto Saegusa, Masahiko Watanabe and Wasaburo Koizumi

      Version of Record online: 10 SEP 2013 | DOI: 10.1002/cncr.28341

      • image
      • image
      • image
      • image

      In an analysis of prognostic factors among patients with pancreatic neuroendocrine tumors, a somatostatin receptor type 2A score of 0 is a significant independent predictor of poor outcomes. The assessment of somatostatin receptor type 2A may facilitate the selection of treatment regimens and the prediction of outcomes.

    3. Genitourinary Disease
      You have free access to this content
      Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer (pages 4103–4110)

      Dylan Zylla, Brett L. Gourley, Derek Vang, Scott Jackson, Sonja Boatman, Bruce Lindgren, Michael A. Kuskowski, Chap Le, Kalpna Gupta and Pankaj Gupta

      Version of Record online: 16 SEP 2013 | DOI: 10.1002/cncr.28345

      • image

      This retrospective study revealed that the level of expression of the mu opioid receptor and greater opioid requirement are associated with shorter progression-free survival and overall survival in patients with metastatic prostate cancer who are treated with androgen deprivation therapy.

    4. Head and Neck Disease
      You have free access to this content
      Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: Interim results from 2 prospective phase 2 clinical trials (pages 4111–4118)

      Lin Kong, Chaosu Hu, Xiaoshuang Niu, Youwang Zhang, Ye Guo, Ivan W. K. Tham and Jiade Jay Lu

      Version of Record online: 27 AUG 2013 | DOI: 10.1002/cncr.28324

      • image
      • image

      Neoadjuvant chemotherapy combined with a taxane, cisplatin, and 5-fluorouracil followed by concurrent chemoradiation is well tolerated and produces encouraging outcomes in patients with locally advanced nasopharyngeal carcinoma in this hypothesis-generating study. Randomized controlled trials are warranted to definitively confirm this aggressive and potentially efficacious strategy.

    5. Hematologic Malignancies
      You have free access to this content
      Bortezomib-containing induction regimens in transplant-eligible myeloma patients : A meta-analysis of phase 3 randomized clinical trials (pages 4119–4128)

      Ajay K. Nooka, Jonathan L. Kaufman, Madhusmita Behera, Amelia Langston, Edmund K. Waller, Christopher R. Flowers, Charise Gleason, Lawrence H. Boise and Sagar Lonial

      Version of Record online: 4 SEP 2013 | DOI: 10.1002/cncr.28325

      • image
      • image
      • image
      • image
      • image

      The receipt of bortezomib-based induction therapy in a meta-analysis of patients with myeloma demonstrates improvement in the depth of response before and after transplant. Bortezomib-based induction is associated with a higher incidence of adverse events but also with improved progression-free and overall survival after transplant.

    6. You have free access to this content
      Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study (pages 4129–4136)

      Peter Martin, Michelle Byrtek, Keith Dawson, Ryan Ziemiecki, Jonathan W. Friedberg, James R. Cerhan, Christopher R. Flowers and Brian K. Link

      Version of Record online: 4 SEP 2013 | DOI: 10.1002/cncr.28350

      • image
      • image

      The majority of patients with follicular lymphoma complete first-line chemoimmunotherapy as intended. Strategies to improve dose delivery appear unlikely to impact outcomes.

    7. Hepatobiliary Disease
      You have free access to this content
      Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases (pages 4137–4144)

      Georgios Karagkounis, Michael S. Torbenson, Hubert D. Daniel, Nilofer S. Azad, Luis A. Diaz Jr, Ross C. Donehower, Kenzo Hirose, Nita Ahuja, Timothy M. Pawlik and Michael A. Choti

      Version of Record online: 19 SEP 2013 | DOI: 10.1002/cncr.28347

      • image
      • image
      • image
      • image

      In this study of molecular biomarkers in patients undergoing surgical therapy of colorectal liver metastasis, KRAS mutations were found in approximately one third of patients, whereas BFAF mutations were found in only 2% of patients. KRAS status was an independent predictor of outcome and, as such, may help to refine our prognostic assessment of patients undergoing surgical therapy for colorectal liver metastases.

    8. Discipline

      Clinical Trials
      You have free access to this content
      Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first-line treatment of metastatic colorectal cancer: Correlation with serum amphiregulin and transforming growth factor alpha (pages 4145–4153)

      Brigette B. Y. Ma, Stephen L. Chan, Wing M. Ho, Wilson Lau, Frankie Mo, Edwin P. Hui, Charles Chan, Annette Poon, Rasalkar D. Dattatray, S. C. Cesar Wong, Ka F. To, Ann D. King, Anil Ahuja and Anthony T. C. Chan

      Version of Record online: 1 OCT 2013 | DOI: 10.1002/cncr.28327

      • image
      • image
      • image
      • image
      • image

      This phase 2 study is the first to evaluate the biological effect of different schedules of erlotinib in metastatic colorectal cancer. This study also demonstrates the prognostic utility of serum epidermal growth factor receptor ligands in erlotinib-treated patients with colorectal cancer.

    9. Pediatric Oncology
      You have free access to this content
      Suggestions from adolescents, young adults, and parents for improving informed consent in phase 1 pediatric oncology trials (pages 4154–4161)

      Justin N. Baker, Angela C. Leek, Halle Showalter Salas, Dennis Drotar, Robert Noll, Susan R. Rheingold and Eric D. Kodish

      Version of Record online: 4 SEP 2013 | DOI: 10.1002/cncr.28335

      Adolescents, young adults, and parents provided suggestions to improve the informed consent process for pediatric phase 1 oncology trials. Themes include providing more information, structure, and presentation of informed consent, and physician-specific suggestions.

    10. You have free access to this content
      Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients : A Report from the Children's Oncology Group (pages 4162–4169)

      Jason Canner, Todd A. Alonzo, Janet Franklin, David R. Freyer, Alan Gamis, Robert B. Gerbing, Beverly J. Lange, Soheil Meshinchi, William G. Woods, John Perentesis and John Horan

      Version of Record online: 19 SEP 2013 | DOI: 10.1002/cncr.28342

      • image
      • image

      Adolescent/young adult patients with newly diagnosed acute myeloid leukemia are as likely to survive as younger patients, but are more likely to die from treatment complications. Infections account for their higher risk of treatment-related mortality.

    11. You have free access to this content
      Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials (pages 4170–4179)

      William G. Woods, Anna R. K. Franklin, Todd A. Alonzo, Robert B. Gerbing, Kathleen A. Donohue, Megan Othus, John Horan, Frederick R. Appelbaum, Elihu H. Estey, Clara D. Bloomfield and Richard A. Larson

      Version of Record online: 19 SEP 2013 | DOI: 10.1002/cncr.28344

      • image
      • image

      Adolescent and young adults with acute myeloid leukemia had equivalent outcomes whether treated on pediatric or adult trials when factoring in age. Pediatric trials led to significantly lower relapse rates as well as higher treatment-related mortality.

    12. You have free access to this content
      Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11) : A Pediatric Brain Tumor Consortium Study (PBTC-022) (pages 4180–4187)

      Jason Fangusaro, Sridharan Gururangan, Tina Young Poussaint, Roger E. McLendon, Arzu Onar-Thomas, Katherine E. Warren, Shengjie Wu, Roger J. Packer, Anu Banerjee, Richard J. Gilbertson, Regina Jakacki, Amar Gajjar, Stewart Goldman, Ian F. Pollack, Henry S. Friedman, James M. Boyett, Larry E. Kun and Maryam Fouladi

      Version of Record online: 19 SEP 2013 | DOI: 10.1002/cncr.28343

      The combination of bevacizumab and irinotecan (CPT-11) was fairly well tolerated in children with recurrent central nervous system tumors. Most severe bevacizumab-related toxicities were rare, self-limiting, and manageable.

    13. Psychosocial Oncology
      You have free access to this content
      Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant (pages 4188–4195)

      Desiree Jones, Elisabeth G. Vichaya, Xin Shelley Wang, Mary H. Sailors, Charles S. Cleeland and Jeffrey S. Wefel

      Version of Record online: 16 SEP 2013 | DOI: 10.1002/cncr.28323

      • image

      Neuropsychological functioning in patients with multiple myeloma in the period immediately following autologous hematopoietic stem cell transplant (AuHSCT) has not been examined. This study reports the incidence of cognitive deficits in patients with multiple myeloma before AuHSCT and clinically significant changes in cognitive function 1 and 3 months post-AuHSCT.

    14. Radiation Oncology
      You have free access to this content
      Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010 (pages 4196–4204)

      Sophie Cai, Theodore S. Hong, Saveli I. Goldberg, Carlos Fernandez-del Castillo, Sarah P. Thayer, Cristina R. Ferrone, David P. Ryan, Lawrence S. Blaszkowsky, Eunice L. Kwak, Christopher G. Willett, Keith D. Lillemoe, Andrew L. Warshaw and Jennifer Y. Wo

      Version of Record online: 4 SEP 2013 | DOI: 10.1002/cncr.28329

      • image
      • image
      • image

      Among 194 patients with unresectable locally advanced pancreatic cancer who received intraoperative radiotherapy as part of their treatment, the 1-year, 2-year, 3-year, and 5-year overall survival rates were 49%, 16%, 6%, and 3%, respectively. Small tumor diameter, low Charlson age-comorbidity index, and receipt of chemotherapy were found to be independently predictive of improved survival, with a median overall survival of 21.2 months for patients with all 3 favorable prognostic factors.

    15. You have free access to this content
      A NEIL1 single nucleotide polymorphism (rs4462560) predicts the risk of radiation-induced toxicities in esophageal cancer patients treated with definitive radiotherapy (pages 4205–4211)

      Yun Chen, Meiling Zhu, Zhen Zhang, Guoliang Jiang, Xiaolong Fu, Min Fan, Menghong Sun, Qingyi Wei and Kuaile Zhao

      Version of Record online: 10 SEP 2013 | DOI: 10.1002/cncr.28338

      • image

      Six potentially functional single nucleotide polymorphisms are genotyped in 3 base-excision repair genes, FEN1, hOGG1, and NEIL1, from 187 patients with esophageal squamous cell carcinoma who received definitive radiotherapy with or without chemotherapy. The results indicate that the NEIL1 rs4462560 polymorphism may serve as a reliable predictor of acute radiation-induced esophageal toxicity and radiation pneumonitis risk.

SEARCH

SEARCH BY CITATION